Oseltamivir Zentiva (Oseltamivir Phosphate)

Oseltamivir, the active ingredient in Oseltamivir Zentiva, is a neuraminidase inhibitor presented as oral tablets for oral use. It treats acute influenza infection and is used for prophylaxis in adults and children at risk of exposure.

GNH USA supplies Oseltamivir Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. With a focus on regulatory compliance and product integrity, GNH USA ensures timely delivery and support for healthcare providers across multiple regions.

Oseltamivir Zentiva is a neuraminidase inhibitor used to manage influenza and to prevent infection in exposed individuals.

Influenza infection (treatment): shortens symptom duration and may reduce complications in patients with acute influenza. Influenza prophylaxis (prevention): lowers the risk of developing influenza after known exposure to the virus. High‑risk populations (e.g., elderly, immunocompromised): provides protective benefit when used as prophylaxis to reduce severe disease.

Oseltamivir Zentiva may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Headache - Abdominal pain

Serious or Rare Side Effects: - Allergic reactions (rash, anaphylaxis) - Neuropsychiatric events (delirium, hallucinations) - Severe skin reactions (Stevens‑Johnson syndrome)

Before prescribing Oseltamivir Zentiva, consider the following precautions.

Assess renal function: dosage may need adjustment in patients with severe renal impairment. Monitor for neuropsychiatric symptoms: especially important in children and adolescents. Avoid use in patients with known hypersensitivity to oseltamivir. Use with caution in pregnancy: classified as category B, discuss benefits and risks with a healthcare professional. Review concomitant medications: evaluate potential drug interactions. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Oseltamivir Zentiva can interact with other medicines; some interactions require avoidance while others need monitoring.

Major Interactions (Avoid): - Co‑administration with probenecid: may increase oseltamivir exposure and risk of adverse effects. - Concurrent use of live attenuated influenza vaccine: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Combination with other neuraminidase inhibitors (e.g., zanamivir): monitor for additive toxicity. - Use with immunosuppressants: monitor for increased infection risk. - Co‑administration with oral contraceptives: no clinically significant interaction, but advise standard monitoring.